An interventional study of UC-MSC infusion in Liver Cirrhosis, sponsored by Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-11-04.
Sponsored by Asia Stem Cell Regenerative Pharmaceutical Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.
Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 107th largest by planned enrollment of the 127 interventional ones that give a count, is one of 13 that started in 2021, is one of 61 with no phase, reaches primary completion later than 6 of the 72 other live ones, and was the 121st registered.
1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:
Fifth Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18+
Air Force Military Medical University, China · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18–80
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital · Sites in China
Ages 30–80
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 20 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 25 · Phase 3 12 · Phase 4 22
First in 2005; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 120 across the 127 interventional studies, 430 across the 86 observational. Of the 60 that completed or were terminated, 6 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 214 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Asia Stem Cell Regenerative Pharmaceutical Co., Ltd. as lead sponsor.
Asia Stem Cell Regenerative Pharmaceutical Co., Ltd. has 1 study filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
14 of the studies in Liver Cirrhosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06779058Shengjing HospitalMR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B | 2026-12-01 |
| NCT06770283Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySpirulina Tablets Treat Liver Fibrosis/Cirrhosis | 2026-12-26 |
| NCT07252102Zhejiang UniversityEffect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients | 2026-12-28 |
| NCT05974904Chongqing Medical UniversityAssociation of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study | 2026-12-28 |
| NCT06762223Xiqiao ZhouHenagliflozin on Liver Fibrosis in Patients with MASLD and T2DM | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 214 studies in Liver Cirrhosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the safety and clinical efficacy of umbilical cord mesenchymal stem cell transplantation for decompensated hepatitis B cirrhosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
UC-MSC infusion by intravenus, 1\*10\^8 cells/dose, 2 doses (apart from 24weeks)
Drug: UC-MSC infusion
UC-MSC infusion by introvenus
Number of Participants with abnormal Total bilirubin
Time frame: Changes from baseline to 72 weeks
Number of Participants with abnormal albumin
Time frame: Changes from baseline to 72 weeks
Ishak Inflammation Rating System
Time frame: Changes from baseline to 72 weeks
Ishak Fibrosis Score
Time frame: Changes from baseline to 72 weeks
Overall survival (OS)
Time frame: Changes from baseline to 72 weeks
HBV-DNA
Time frame: Changes from baseline to 72 weeks
incidence of liver cancer
Time frame: Changes from baseline to 72 weeks
Number of Participants with abnormal immunoglobulin
Time frame: Changes from baseline to 72 weeks
portal vein flow rate
Time frame: Changes from baseline to 72 weeks
portal vein width
Time frame: Changes from baseline to 72 weeks
abdominal volume
Time frame: Changes from baseline to 72 weeks
Number of Participants with abnormal coagulation function
Time frame: Changes from baseline to 72 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2021; primary completion for Dec 2024, 36 months later.
Of 215 interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 36 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solizmestrocel